Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

An oral PCSK9 inhibitor, enlicitide, demonstrated a significant 57.1% reduction in LDL cholesterol in the CORALreef Lipids study, comparable to existing injectable therapies like alirocumab and evolocumab. This development is poised to address the low utilization of current PCSK9 inhibitors by overcoming patient aversion to injections and physician prescribing barriers, potentially expanding market adoption among high-risk cardiovascular patients. While promising, a large cardiovascular outcomes study (CORALreef Outcomes) is still ongoing with results years away, and regulatory approval and pricing will be critical factors for its commercial success.

Analysis

Enlicitide, an oral PCSK9 inhibitor, demonstrated a significant 57.1% reduction in LDL cholesterol at 24 weeks in the CORALreef Lipids study, compared to a 3.0% increase in the placebo group (P < 0.001). This efficacy, observed in 2,912 high-risk patients, is comparable to established injectable PCSK9 inhibitors like alirocumab and evolocumab. High tolerability was noted, with 85% of patients continuing into an open-label extension.

The oral formulation represents a substantial market opportunity by addressing patient aversion to injections and physician prescribing complexities, which have limited the uptake of current PCSK9 therapies. This convenience is expected to broaden access and increase utilization among eligible high-risk cardiovascular patients, potentially expanding the overall PCSK9 inhibitor market beyond its current under-1% penetration.

However, significant uncertainties persist. A large cardiovascular outcomes study (CORALreef Outcomes) with over 14,500 subjects is ongoing, with results crucial for demonstrating hard clinical event reduction and are years away. Regulatory approval and the eventual pricing strategy for enlicitide will also be critical determinants of its commercial success, given historical challenges faced by injectable PCSK9 inhibitors regarding cost and insurance coverage.

Key Decisions for Investors

• Monitor the progress and eventual results of the CORALreef Outcomes study, as positive cardiovascular outcomes data will be critical for enlicitide's long-term market potential and regulatory approval
• Evaluate the competitive landscape, particularly the pricing strategies of existing injectable PCSK9 inhibitors (Amgen, Regeneron, Sanofi) and how enlicitide's eventual pricing will position it in the market
• Assess the potential market expansion for PCSK9 inhibitors as a class due to the oral formulation, considering the impact on companies developing or marketing similar therapies